295 related articles for article (PubMed ID: 16786333)
41. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
O'connor T; Rustum Y; Levine E; Creaven P
Cancer Chemother Pharmacol; 2008 Jan; 61(1):125-31. PubMed ID: 17426973
[TBL] [Abstract][Full Text] [Related]
42. [High-dose Tegafur (FT) for primary lung cancer: a phase I trial].
Matsui K; Fukuoka M; Masuda N; Kusunoki Y; Negoro S; Takada M; Ryu S; Sakai N; Takifuji S; Kudoh S
Gan To Kagaku Ryoho; 1991 Apr; 18(4):593-9. PubMed ID: 2012401
[TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
[TBL] [Abstract][Full Text] [Related]
44. [Pharmacokinetics of S-1].
Hirata K; Horikoshi N; Tominaga K; Sohma K; Yamaguchi K; Okazaki M; Furuhata T; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Yamamitsu S; Shirasaka T
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():27-35. PubMed ID: 16897969
[TBL] [Abstract][Full Text] [Related]
45. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
[TBL] [Abstract][Full Text] [Related]
46. Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma.
Shirao K; Ohtsu A; Takada H; Mitachi Y; Hirakawa K; Horikoshi N; Okamura T; Hirata K; Saitoh S; Isomoto H; Satoh A
Cancer; 2004 Jun; 100(11):2355-61. PubMed ID: 15160338
[TBL] [Abstract][Full Text] [Related]
47. Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients.
Campone M; Rademaker-Lakhai JM; Bennouna J; Howell SB; Nowotnik DP; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2007 Sep; 60(4):523-33. PubMed ID: 17308894
[TBL] [Abstract][Full Text] [Related]
48. Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors.
Overman MJ; Kopetz S; Varadhachary G; Fukushima M; Kuwata K; Mita A; Wolff RA; Hoff P; Xiong H; Abbruzzese JL
Cancer Invest; 2008 Oct; 26(8):794-9. PubMed ID: 18798063
[TBL] [Abstract][Full Text] [Related]
49. Phase I/II study of a combination of S-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer.
Kawabata R; Fujiwara Y; Doki Y; Fujita J; Tsukahara Y; Yamasaki M; Miyata H; Takiguchi S; Monden M
Oncology; 2007; 72(3-4):219-25. PubMed ID: 18176087
[TBL] [Abstract][Full Text] [Related]
50. Phase I study of two schedules of oral S-1 in combination with fixed doses of oxaliplatin and bevacizumab in patients with advanced solid tumors.
Chung KY; Saito K; Zergebel C; Hollywood E; Segal M; Saltz LB
Oncology; 2011; 81(2):65-72. PubMed ID: 21968463
[TBL] [Abstract][Full Text] [Related]
51. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
[TBL] [Abstract][Full Text] [Related]
52. Preoperative radiotherapy combined with S-1 for advanced lower rectal cancer: phase I trial.
Morimoto S; Shimada M; Kurita N; Sato H; Iwata T; Nishioka M; Yoshikawa K; Miyatani T; Kashihara H; Takasu C; Ikushima H
Hepatogastroenterology; 2012; 59(117):1428-32. PubMed ID: 22155856
[TBL] [Abstract][Full Text] [Related]
53. Final results of a phase I and pharmacokinetic study of gamma-methylene-10-deazaaminopterin (MDAM) administered intravenously daily for five consecutive days in patients with solid tumors.
Johansen M; Zukowski T; Hoff PM; Newman RA; Ni D; Hutto T; Abbruzzeese J; Berghorn E; Hausheer F; Madden T
Cancer Chemother Pharmacol; 2004 May; 53(5):370-6. PubMed ID: 15060739
[TBL] [Abstract][Full Text] [Related]
54. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.
Ryan QC; Headlee D; Acharya M; Sparreboom A; Trepel JB; Ye J; Figg WD; Hwang K; Chung EJ; Murgo A; Melillo G; Elsayed Y; Monga M; Kalnitskiy M; Zwiebel J; Sausville EA
J Clin Oncol; 2005 Jun; 23(17):3912-22. PubMed ID: 15851766
[TBL] [Abstract][Full Text] [Related]
55. Phase I study of combination therapy with S-1 and weekly docetaxel for advanced gastric cancer.
Ozaki T; Tamura K; Satoh T; Kurata T; Shimizu T; Miyazaki M; Okamoto I; Nakagawa K; Fukuoka M
Anticancer Res; 2007; 27(4C):2657-65. PubMed ID: 17695429
[TBL] [Abstract][Full Text] [Related]
56. [A phase I study of postoperative combination therapy with TS-1 and low dose cisplatin against stage IV gastric carcinoma].
Sato Y; Kondo M; Takahashi M; Une Y; Homma S; Shoumura H; Maeda Y; Oshima T; Kohashi S; Nakano S; Todo S
Gan To Kagaku Ryoho; 2007 Apr; 34(4):563-7. PubMed ID: 17431342
[TBL] [Abstract][Full Text] [Related]
57. Phase I trial of orally administered pentosan polysulfate in patients with advanced cancer.
Marshall JL; Wellstein A; Rae J; DeLap RJ; Phipps K; Hanfelt J; Yunmbam MK; Sun JX; Duchin KL; Hawkins MJ
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2347-54. PubMed ID: 9815633
[TBL] [Abstract][Full Text] [Related]
58. [Phase I study of S-1. S-1 Study Group].
Taguchi T; Inuyama Y; Kanamaru R; Hasegawa K; Akazawa S; Niitani H; Furue H; Kurihara M; Ota K; Suga S; Ariyoshi Y; Takai S; Shimoyama T; Toge T; Takashima S; Sugimachi K; Hara Y; Fujita H; Kimura K; Saito T; Tsukagoshi S; Nakao I
Gan To Kagaku Ryoho; 1997 Dec; 24(15):2253-64. PubMed ID: 9422070
[TBL] [Abstract][Full Text] [Related]
59. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
[TBL] [Abstract][Full Text] [Related]
60. Phase II tailored S-1 regimen study of first-line chemotherapy in elderly patients with advanced and recurrent non-small cell lung cancer.
Shiroyama T; Kijima T; Komuta K; Yamamoto S; Minami S; Ogata Y; Okafuji K; Imamura F; Hirashima T; Tachibana I; Kawase I; Kumanogoh A
Cancer Chemother Pharmacol; 2012 Dec; 70(6):783-9. PubMed ID: 22960985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
